Company Beleave Inc. Canadian Securities Exchange
Equities
BE
CA0775611084
Pharmaceuticals
Business Summary
Sales per Business
USD in Million | 2018 | Weight | 2019 | Weight | Delta |
---|---|---|---|---|---|
Cannabis Products
59.3
%
| - | - | 1 | 59.3 % | - |
Patient Network
40.7
%
| - | - | 1 | 40.7 % | - |
Sales per region
USD in Million | 2018 | Weight | 2019 | Weight | Delta |
---|---|---|---|---|---|
Canada
100.0
%
| 0 | nan % | 2 | 100.0 % | - |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Founder | - | 00-05-25 | |
Roger Ferreira
CTO | Chief Tech/Sci/R&D Officer | - | 15-12-14 |
Kevin Keagan
BRD | Director/Board Member | - | 18-10-23 |
Grant McLeod
IRO | Public Communications Contact | 46 | 18-06-30 |
Paul Evanov
SAM | Sales & Marketing | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Roger Ferreira
CTO | Chief Tech/Sci/R&D Officer | - | 15-12-14 |
Founder | - | 00-05-25 | |
Kevin Keagan
BRD | Director/Board Member | - | 18-10-23 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 518,193,558 | 509,860,225 ( 98.39 %) | 0 | 98.39 % |
Company contact information
Beleave, Inc.
2030 Bristol Circle Suite 115
L6H 0H2, Oakville
+
Sector
Sales per Business
1st Jan change | Capi. | |
---|---|---|
+40.29% | 6.16B | |
-15.73% | 4.49B | |
-9.40% | 3.17B | |
-1.60% | 3.01B | |
-1.23% | 2.57B | |
+34.89% | 1.8B | |
-11.37% | 1.62B | |
-5.02% | 1.56B | |
-13.21% | 1.53B |